231 related articles for article (PubMed ID: 31435830)
1. Burden of Asthma and Role of 2.5 µg Tiotropium Respimat
Mansfield L; Duong-Quy S; Craig T
Adv Ther; 2019 Oct; 36(10):2587-2599. PubMed ID: 31435830
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.
Dahl R; Engel M; Dusser D; Halpin D; Kerstjens HAM; Zaremba-Pechmann L; Moroni-Zentgraf P; Busse WW; Bateman ED
Respir Med; 2016 Sep; 118():102-111. PubMed ID: 27578478
[TBL] [Abstract][Full Text] [Related]
3. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
[TBL] [Abstract][Full Text] [Related]
4. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
[TBL] [Abstract][Full Text] [Related]
5. Tiotropium in children and adolescents with asthma.
Murphy KR; Chipps BE
Ann Allergy Asthma Immunol; 2020 Mar; 124(3):267-276.e3. PubMed ID: 31805357
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.
Paggiaro P; Halpin DM; Buhl R; Engel M; Zubek VB; Blahova Z; Moroni-Zentgraf P; Pizzichini E
J Allergy Clin Immunol Pract; 2016; 4(1):104-13.e2. PubMed ID: 26563670
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium added to low- to medium-dose inhaled corticosteroids (ICS) versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma: A systematic review and meta-analysis.
Wang L; Zhou R; Xie X
J Asthma; 2019 Jan; 56(1):69-78. PubMed ID: 29420077
[TBL] [Abstract][Full Text] [Related]
9. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S
Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298
[TBL] [Abstract][Full Text] [Related]
10. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.
Beeh KM; Moroni-Zentgraf P; Ablinger O; Hollaenderova Z; Unseld A; Engel M; Korn S
Respir Res; 2014 Jun; 15(1):61. PubMed ID: 24890738
[TBL] [Abstract][Full Text] [Related]
11. Safety of tiotropium Respimat
Graham LM; Kerstjens HAM; Vogelberg C; Hamelmann E; Szefler SJ; Pisternick-Ruf W; Engel M; El Azzi G; Unseld A; Foggs MB
Respir Med; 2019 Aug; 155():58-60. PubMed ID: 31302579
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5.
Buhl R; FitzGerald JM; Meltzer EO; de la Hoz A; Sigmund R; Kerstjens HAM; Bleecker ER
Pulm Pharmacol Ther; 2020 Feb; 60():101881. PubMed ID: 31874283
[TBL] [Abstract][Full Text] [Related]
13. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma.
Szefler SJ; Murphy K; Harper T; Boner A; Laki I; Engel M; El Azzi G; Moroni-Zentgraf P; Finnigan H; Hamelmann E
J Allergy Clin Immunol; 2017 Nov; 140(5):1277-1287. PubMed ID: 28189771
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium for the treatment of asthma in adolescents.
Hamelmann E; Vogelberg C; Szefler SJ
Expert Opin Pharmacother; 2017 Feb; 18(3):305-312. PubMed ID: 28110558
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium Respimat®: A Review of Its Use in Asthma Poorly Controlled with Inhaled Corticosteroids and Long-Acting β2-Adrenergic Agonists.
McKeage K
Drugs; 2015 May; 75(7):809-16. PubMed ID: 25895466
[TBL] [Abstract][Full Text] [Related]
16. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial.
Hamelmann E; Bateman ED; Vogelberg C; Szefler SJ; Vandewalker M; Moroni-Zentgraf P; Avis M; Unseld A; Engel M; Boner AL
J Allergy Clin Immunol; 2016 Aug; 138(2):441-450.e8. PubMed ID: 26960245
[TBL] [Abstract][Full Text] [Related]
17. Long-acting inhaled bronchodilators for cystic fibrosis.
Smith S; Edwards CT
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD012102. PubMed ID: 29253920
[TBL] [Abstract][Full Text] [Related]
18. Tiotropium – what role in asthma?
Drug Ther Bull; 2015 Sep; 53(9):102-4. PubMed ID: 26358316
[TBL] [Abstract][Full Text] [Related]
19. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status.
Kerstjens HA; Moroni-Zentgraf P; Tashkin DP; Dahl R; Paggiaro P; Vandewalker M; Schmidt H; Engel M; Bateman ED
Respir Med; 2016 Aug; 117():198-206. PubMed ID: 27492532
[TBL] [Abstract][Full Text] [Related]
20. Tiotropium Respimat® add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics.
Casale TB; Aalbers R; Bleecker ER; Meltzer EO; Zaremba-Pechmann L; de la Hoz A; Kerstjens HAM
Respir Med; 2019; 158():97-109. PubMed ID: 31654891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
